Lipotoxicity: Why do saturated fatty acids cause and monounsaturates protect against it?
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Saturated fatty acids (SFA) (e.g. palmitate [16 : 0]) are almost universally toxic to cells in culture, whereas the monounsaturated fatty acids (MUFA) (e.g. oleate [18 : 1]) are either non-toxic or cytoprotective. The opposing effects of SFA and MUFA have been observed in multiple cell types including islet β-cells,1 endothelial cells,2 cardiomyocytes,3 breast cancer cell lines,4,5 and in hepatocyte cell lines as shown by Ricchi et al. in this issue of the Journal.6 Importantly, the addition of MUFA to cell cultures dose-dependently inhibits SFA-induced cell death. Elevated glucose clearly increases the toxicity of palmitate in β-cells, a process called glucolipotoxicity.1 The role of elevated glucose on lipotoxicity in other cell types has been under-investigated. An understanding of the mechanisms by which SFA are cytotoxic and MUFA are cytoprotective may give us clues to novel therapeutic approaches for relevant conditions, whether by diet or pharmacotherapeutic means. In most circumstances (e.g. steatohepatitis complicating non-alcoholic fatty liver disease [NAFLD]) the aim will be to inhibit cytotoxicity and/or promote cytoprotection. In some situations, however, inhibition of MUFA-induced cytoprotective mechanisms may have a role (e.g. in cancer therapy). So, why do the differing fatty acid types behave so differently with respect to cell survival? Fatty acids and their metabolites have numerous biological functions.7 Not only are lipids the major form by which energy is stored, they are also involved in cell structure, and participate in intracellular, extracellular and whole animal (endocrine) signaling processes. It should be no surprise, therefore, that the metabolism and behavior of the various types of fatty acids differs greatly. Considering this, it is probable that the mechanisms and/or pathways involved in SFA-induced cytotoxicity will be multiple and differ from those of MUFA-mediated cytoprotection. Fatty acids may exert their effects directly, for example as ligands to cell surface receptors (e.g. G-protein coupled receptors [GPCR]) or to intracellular transcription factors (e.g. peroxisome proliferator-activated receptors [PPAR]). Alternatively, fatty acids may need to be metabolized intracellularly to have their effects. There is evidence for both these direct and indirect effects influencing cell viability. The mechanisms, however, remain to be clearly defined. A few previously orphaned GPCR have been discovered to be cell surface receptors for fatty acids (GPR40, 41, 43 and 120).8 The most studied is GPR40, which is highly expressed in pancreatic islet β-cells and brain.9 This receptor is known to have a role in fatty acid augmentation of glucose-stimulated insulin secretion.9,10 Interestingly, GPR40 may have a role in oleate-induced protection against palmitate-induced apoptosis, as shown in the mouse β-cell line NIT1,11 and in various breast cancer cell lines.12 The effects are possibly via the phospholipase C, mitogen-extracellular signal-regulated kinase 1/2, Src, and phosphatidyl 3-kinase/protein kinase B signaling pathways.12 However, medium to long chain SFA and MUFA seem to be similarly active ligands for GPR40,9 such that it is difficult to explain why oleate induces cytoprotection via this pathway, yet SFA do not. While GPR40 is believed to be minimally expressed in liver, in certain situations its expression might be induced as has recently been demonstrated in primary chicken hepatocytes cultured in the presence of linoleic acid.13 There may be other cell surface receptors that respond more specifically to MUFA or their metabolites. For example, GPR119 is another GPCR for which N-oleoylethanolamine (OEA), an endogenous cannabinoid-like compound, is a ligand.14 Further studies are required to clarify whether GPCR have any roles in mediating lipotoxicity. Peroxisome proliferator-activated receptors are a family of nuclear receptors (PPARα, β/δ and γ) that are activated by fatty acid ligands. They play key roles as lipid/nutritional state sensors and transcriptional regulators of lipid metabolism.15 As MUFA are more potent PPAR ligands than SFA, it is plausible that PPAR activation may explain the different effects of MUFA on cell viability.15 Interestingly, the endogenous cannabinoid-like compounds, including OEA, have also been found to be PPARα agonists and to be neuroprotective following stroke in mice.16 PPAR activation results in altered intracellular fatty acid metabolism, such that the intracellular partitioning of all fatty acids will be altered. Thus, direct PPAR activation by oleate may promote oxidation or sequestration of palmitate, thereby preventing subsequent cytotoxicity. Activated PPARα not only induces the transcription of genes of peroxisomal and mitochondrial β-oxidation,15,17 but also inhibits the pro-inflammatory nuclear factor (NF)-κB. In pancreatic β-cells and in breast cancer cells, fatty acid oxidation activation by pharmacological means reduced lip
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Islet cell failure in type 2 diabetes
Prentki, M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29103 · Cited by 1,690
Free fatty acids regulate insulin secretion from pancreatic β cells through GPR40
Itoh, Y., Kawamata, Y., Harada, M., Kobayashi, M., Fujii, R., Fukusumi, S., Ogi, K., Hosoya, M., Tanaka, Y., Uejima, H., et al. (2003) · Nature · doi:10.1038/nature01478 · Cited by 1,538
Oleate prevents palmitate-induced cytotoxic stress in cardiac myocytes
Miller, T. A., LeBrasseur, N. K., Cote, G. M., Trucillo, M. P., Pimentel, D. R., Ido, Y., Ruderman, N. B., & Sawyer, D. B. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.08.088 · Cited by 146
Role of the endocannabinoid system in metabolic control
Wang, J., & Ueda, N. (2008) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e3282f29071 · Cited by 17
Cited by
Neuschwander‐Tetri, B. A. (2010) · Hepatology · doi:10.1002/hep.23719 · Cited by 1,077
The interaction of hepatic lipid and glucose metabolism in liver diseases
Bechmann, L. P., Hannivoort, R. A., Gerken, G., Hotamisligil, G. S., Trauner, M., & Canbay, A. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.08.025 · Cited by 994
From NAFLD to NASH to cirrhosis—new insights into disease mechanisms
Wree, A., Broderick, L., Canbay, A., Hoffman, H. M., & Feldstein, A. E. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.149 · Cited by 609
From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
Gastaldelli, A., & Cusi, K. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.07.002 · Cited by 455
NASH is an Infl ammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications
Farrell, G. C., Rooyen, D. V., Gan, L., & Chitturi, S. (2012) · Gut and Liver · doi:10.5009/gnl.2012.6.2.149 · Cited by 398
Metadata
- Authors
- Nolan, C. J., & Larter, C. Z.
- Venue
- Journal of Gastroenterology and Hepatology
- Publisher
- Wiley
- Published
- 2009-05
- Volume
- 24
- Issue
- 5
- Pages
- 703-706
- ISSN
- 0815-9319 (ISSN-L)
- 1440-1746
- OpenAlex
- W1988320060
- Cited by
- 134
- References
- 4
- FWCI
- 2.56
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lipotoxicity: Why do saturated fatty acids cause and monounsaturates protect against it? https://app.cochat.ai/papers/10.1111/j.1440-1746.2009.05823.x
- The paper
- Nolan, C. J., & Larter, C. Z. (2009). Lipotoxicity: Why do saturated fatty acids cause and monounsaturates protect against it? Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/j.1440-1746.2009.05823.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.